Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EpiCept cancer, neurology news

EpiCept will reduce headcount by 65% to 13 over the next six months and discontinue its drug discovery

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE